TABLE 1.
Demographics and clinical characteristics of blood eosinophillow and blood eosinophilhigh patients
| EosinophilLow (n = 21) | EosinophilHigh (n = 20) | P value | |
|---|---|---|---|
| Age (years)(1) | 61.6 (5.9) | 62.2 (4.4) | .70 |
| Gender (% Male)(3) | 57 | 70 | .52 |
| Current smokers (%)(3) | 43 | 60 | .35 |
| Smoking pack‐years history(1) | 41.5 (15.2) | 37.7 (14.0) | .41 |
| ICS users (n)(3) | 16 | 11 | .20 |
| GOLD Stage 1 (n) (3) | 1 | 1 | 1.00 |
| GOLD Stage 2 (n) (3) | 18 | 18 | 1.00 |
| GOLD Stage 3 (n) (3) | 2 | 1 | 1.00 |
| Post‐bronchodilator FEV1 (L)(1) | 1.79 (0.43) | 1.89 (0.40) | .45 |
| Post‐bronchodilator FEV1 (% Predicted)(1) | 62.4 (11.2) | 65.5 (10.9) | .38 |
| Post‐bronchodilator FVC (L)(1) | 3.72 (1.16) | 3.62 (0.87) | .77 |
| Post‐bronchodilator FEV1/FVC ratio(1) | 0.50 (0.1) | 0.53 (0.1) | .34 |
| Reversibility (ml)(1) | 189.5 (183.1) | 219.5 (153.8) | .57 |
| Reversibility (%)(1) | 13.1 (11.8) | 15.3 (13.9) | .58 |
| FeNO50 (ppm)(2) | 14.8 [5.0‐30.0] | 21.0 [2.2‐61.0] | .24 |
| BMI (kg/m2)(2) | 29.2 [17.9‐33.8] | 25.5 [18.7‐32.2] | .11 |
| Total SGRQ(1) | 42.3 (15.2) | 36.6 (21.3) | .37 |
| mMRC(2) | 1 [1‐4] | 1 [0‐4] | .10 |
| CAT(2) | 17 [5‐35] | 17 [4‐32] | .48 |
| 0 exacerbations, 12 month prior (n)(3) | 12 | 13 | .75 |
| 1 exacerbations, 12 month prior (n)(3) | 4 | 3 | 1.00 |
| ≥2 exacerbations, 12 month prior (n)(3) | 5 | 4 | 1.00 |
| White blood cell count (×109/L)(1) | 7.03 (1.62) | 7.57 (1.91) | .34 |
| Blood eosinophil count (×109/L)(1) | 0.10 (0.03) | 0.43 (0.15) | <.0001 |
| Blood neutrophil count (×109/L)(1) | 4.40 (1.33) | 4.25 (1.45) | .75 |
| Blood lymphocyte count (×109/L)(1) | 1.85 (0.50) | 2.14 (0.64) | .12 |
| Blood monocyte count (×109/L)(1) | 0.61 (0.16) | 0.68 (0.25) | .25 |
| Blood basophil count (×109/L)(1) | 0.04 (0.03) | 0.06 (0.02) | .03 |
Data presented as number, %, mean (SD) or median [range]. Comparisons between EosinophilLow and EosinophilHigh were by: (1) t test; (2) Mann–Whitney or (3) Fisher's exact test.
Abbreviations: BMI, Body Mass Index; CAT, COPD Assessment Test; FEV1, Forced Expired Volume in first second; FVC, Forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease (FEV1% predicted: GOLD stage 1: ≥80%; GOLD stage 2:79%‐50%; GOLD stage 3:49%‐30%); ICS, Inhaled corticosteroid use; mMRC, modified Medical Research Council; SGRQ, St George's Respiratory Questionnaire.